HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Looareesuwan, S. Articles by Canfield, C. J. Search for Related Content PubMed PubMed Citation Articles by Looareesuwan, S. Articles by Canfield, C. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATOVAQUONE

Clinical Studies of Atovaquone, Alone or in Combination with other Antimalarial Drugs, for Treatment of Acute Uncomplicated Malaria in Thailand

The therapy of Plasmodium falciparum malaria continues to be a problem in many parts of Southeast Asia because of multidrug resistance to nearly all existing antimalarial drugs. Atovaquone is a novel hydroxynaphthoquinone with broad spectrum anti-protozoal activity. We recently evaluated the antimalarial activity of atovaquone in a series of dose-ranging studies in 317 patients with malaria at the Bangkok Hospital for Tropical Diseases. Originally, the drug was administered alone. Using atovaquone alone resulted in satisfactory, initial clinical responses in all patients; the mean parasite and fever clearance times were 62 and 53 hr, respectively. However, irrespective of the duration of therapy, overall cure rates were approximately 67%. In vitro sensitivity studies on parasites taken from patients prior to treatment and at the time of recrudescence showed a marked decrease in susceptibility to atovaquone in the recrudescent parasites. To improve cure rates, atovaquone was administered in combination with other drugs with antimalarial activity. Proguanil and tetracycline were chosen due to laboratory evidence of potentiation; doxycycline was selected because it has a longer half-life than tetracycline. Although pyrimethamine did not show laboratory evidence of potentiation with atovaquone, it was chosen as an alternative inhibitor of dihydrofolic acid reductase with a longer half-life than proguanil. The clinical studies with these drug combinations confirmed the laboratory results with marked improvement in cure rates for proguanil, tetracycline, and doxycycline; pyrimethamine showed only minimal improvement. Proguanil was subsequently selected as the preferred drug partner because of its long record of safety and the ability to use the drug in pregnant women and children. Of the 104 patients with falciparum malaria treated with atovaquone plus proguanil for 3–7 days, 101 were cured and had virtually no adverse side effects. The combination of atovaquone and proguanil also was effective in eliminating erythrocytic forms of P. vivax, but parasitemia recurred in most patients.

This article has been cited by other articles:

				M. E. Polhemus, S. Remich, B. Ogutu, J. Waitumbi, M. Lievens, W. R. Ballou, and D. G. Heppner Jr. Malaria Treatment with Atovaquone-Proguanil in Malaria-Immune Adults: Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1493 - 1495. [Abstract] [Full Text] [PDF]

				M. D. Edstein, B. M. Kotecka, A. L. Ager, K. S. Smith, C. A. DiTusa, D. S. Diaz, D. E. Kyle, G. A. Schiehser, D. P. Jacobus, K. H. Rieckmann, et al. Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate JPC2056 in cynomolgus monkeys using an in vivo in vitro model J. Antimicrob. Chemother., October 1, 2007; 60(4): 811 - 818. [Abstract] [Full Text] [PDF]

				L. Musset, J. Le Bras, and J. Clain Parallel Evolution of Adaptive Mutations in Plasmodium falciparum Mitochondrial DNA During Atovaquone-Proguanil Treatment Mol. Biol. Evol., August 1, 2007; 24(8): 1582 - 1585. [Abstract] [Full Text] [PDF]

				E. Legrand, M. Demar, B. Volney, M.-T. Ekala, M. Quinternet, C. Bouchier, T. Fandeur, C. Rogier, B. Carme, O. M. Puijalon, et al. First Case of Emergence of Atovaquone Resistance in Plasmodium falciparum during Second-Line Atovaquone-Proguanil Treatment in South America Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2280 - 2281. [Full Text] [PDF]

				K. S. Griffith, L. S. Lewis, S. Mali, and M. E. Parise Treatment of Malaria in the United States: A Systematic Review JAMA, May 23, 2007; 297(20): 2264 - 2277. [Abstract] [Full Text] [PDF]

				A. K. BOGGILD, M. E. PARISE, L. S. LEWIS, and K. C. KAIN ATOVAQUONE-PROGUANIL: REPORT FROM THE CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS (II) Am J Trop Med Hyg, February 1, 2007; 76(2): 208 - 223. [Abstract] [Full Text] [PDF]

				A. B. S. Sidhu, Q. Sun, L. J. Nkrumah, M. W. Dunne, J. C. Sacchettini, and D. A. Fidock In Vitro Efficacy, Resistance Selection, and Structural Modeling Studies Implicate the Malarial Parasite Apicoplast as the Target of Azithromycin J. Biol. Chem., January 26, 2007; 282(4): 2494 - 2504. [Abstract] [Full Text] [PDF]

				J. P. Daily Antimalarial drug therapy: the role of parasite biology and drug resistance. J. Clin. Pharmacol., December 1, 2006; 46(12): 1487 - 1497. [Abstract] [Full Text] [PDF]

				L. Musset, B. Pradines, D. Parzy, R. Durand, P. Bigot, and J. Le Bras Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers J. Antimicrob. Chemother., January 1, 2006; 57(1): 110 - 115. [Abstract] [Full Text] [PDF]

				F. MI-ICHI, H. MIYADERA, T. KOBAYASHI, S. TAKAMIYA, S. WAKI, S. IWATA, S. SHIBATA, and K. KITA Parasite Mitochondria as a Target of Chemotherapy: Inhibitory Effect of Licochalcone A on the Plasmodium falciparum Respiratory Chain Ann. N.Y. Acad. Sci., November 1, 2005; 1056(1): 46 - 54. [Abstract] [Full Text] [PDF]

				M. W. Mather, E. Darrouzet, M. Valkova-Valchanova, J. W. Cooley, M. T. McIntosh, F. Daldal, and A. B. Vaidya Uncovering the Molecular Mode of Action of the Antimalarial Drug Atovaquone Using a Bacterial System J. Biol. Chem., July 22, 2005; 280(29): 27458 - 27465. [Abstract] [Full Text] [PDF]

				J. J. Kessl, P. Hill, B. B. Lange, S. R. Meshnick, B. Meunier, and B. L. Trumpower Molecular Basis for Atovaquone Resistance in Pneumocystis jirovecii Modeled in the Cytochrome bc1Complex of Saccharomyces cerevisiae J. Biol. Chem., January 23, 2004; 279(4): 2817 - 2824. [Abstract] [Full Text] [PDF]

				E. Schwartz, M. Parise, P. Kozarsky, and M. Cetron Delayed Onset of Malaria -- Implications for Chemoprophylaxis in Travelers N. Engl. J. Med., October 16, 2003; 349(16): 1510 - 1516. [Abstract] [Full Text] [PDF]

				J. A. Kovacs, V. J. Gill, S. Meshnick, and H. Masur New Insights Into Transmission, Diagnosis, and Drug Treatment of Pneumocystis carinii Pneumonia JAMA, November 21, 2001; 286(19): 2450 - 2460. [Abstract] [Full Text] [PDF]